Key result
Statin use linked to ~47% lower colorectal cancer risk in IBD.
Why the study?
Does statin use reduce the risk of colorectal cancer in patients with inflammatory bowel disease?
Meta-Analysis (n=22,250)
Does statin use reduce the risk of colorectal cancer in patients with inflammatory bowel disease?
Relative Risk: 1.88 (95% CI 1.54–2.3)
Authors
No takes yet. Share an insight, caveat, or question.
Statin use appears to be associated with a reduced risk of colorectal cancer in patients with inflammatory bowel disease.
Li et al. (2024) conducted a meta-analysis in Inflammatory bowel disease (IBD) (n=22,250). Statin use vs. Non-users was evaluated on Colorectal cancer (CRC) (RR 1.88, 95% CI 1.54-2.30). Statin use was associated with a significantly lower risk of colorectal cancer in patients with inflammatory bowel disease compared to non-users (RR 1.88; 95% CI 1.54-2.30).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: